12 months of anticoagulation found to improve outcomes in cancer patients with minor blood clots

by

Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

Leave A Comment

Your email address will not be published. Required fields are marked *